Benzinga · Oct 15, 2026
Citigroup Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $39
Citigroup analyst Geoff Meacham maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $32 to $39.
AM
NASDAQ · AMLX
Amylyx Pharmaceuticals, Inc.
Healthcare · Biotechnology
$28.86
Up+$0.18 (+0.63%)
Updated Nov 1, 2026, 9:01 AM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.26B
- P/E ratio
- -9.48
- Dividend yield
- 0.00%
- 52-week range
- $12.44 – $41.14
- Volume
- 989.52K
- Avg. volume
- 1.42M
Price performance · AMLX
AMLX price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
AMLX closed at $28.86 after 20 trading sessions, up 3.89% for the selected period.
- Last close
- $28.86
- Period change
- +3.89%
- Period low
- $26.34
- Period high
- $29.03
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $28.41 | $29.09 | $28.00 | $28.86 | 989.52K |
| Oct 29, 2026 | $28.13 | $29.13 | $28.095 | $28.68 | 905.47K |
| Oct 28, 2026 | $28.11 | $28.48 | $27.58 | $28.07 | 1.07M |
| Oct 27, 2026 | $27.28 | $28.32 | $26.855 | $28.30 | 1.12M |
| Oct 26, 2026 | $27.25 | $27.98 | $26.23 | $27.09 | 1.37M |
| Oct 23, 2026 | $28.46 | $28.46 | $27.06 | $27.20 | 1.16M |
| Oct 22, 2026 | $28.84 | $30.00 | $28.51 | $28.57 | 1.31M |
| Oct 21, 2026 | $28.96 | $29.775 | $28.81 | $29.03 | 1.63M |
| Oct 20, 2026 | $27.54 | $29.23 | $27.15 | $28.77 | 1.61M |
| Oct 19, 2026 | $26.48 | $27.35 | $26.27 | $27.33 | 1.38M |
| Oct 16, 2026 | $27.65 | $27.65 | $26.20 | $26.34 | 1.15M |
| Oct 15, 2026 | $27.68 | $28.34 | $27.45 | $27.65 | 882.66K |
| Oct 14, 2026 | $26.80 | $27.77 | $26.46 | $27.03 | 1.17M |
| Oct 13, 2026 | $27.49 | $27.69 | $26.80 | $26.85 | 1.06M |
| Oct 12, 2026 | $28.04 | $28.49 | $27.40 | $27.48 | 1.11M |
| Oct 9, 2026 | $27.32 | $28.60 | $26.94 | $28.14 | 1.47M |
| Oct 8, 2026 | $27.01 | $27.53 | $26.04 | $27.20 | 2.62M |
| Oct 7, 2026 | $27.72 | $28.46 | $27.21 | $27.43 | 2.06M |
| Oct 6, 2026 | $27.97 | $28.4988 | $27.00 | $28.04 | 1.28M |
| Oct 5, 2026 | $27.92 | $28.09 | $27.34 | $27.78 | 941.08K |
Latest AMLX news
The latest Smart Investors Daily articles mentioning AMLX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
AMLX research
Overview
Company profile and research snapshot.
Company profile
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $20.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 15, 2026 | Citigroup | Buy | — |
| Aug 27, 2026 | Guggenheim | Buy | — |
| Aug 19, 2026 | Guggenheim | Buy | — |
| Aug 19, 2026 | Mizuho | Outperform | — |
| Aug 19, 2026 | Baird | Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 6, 2026
Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
CAMBRIDGE, Mass., October 06, 2026--Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in PBH at ObesityWeek® 2026 Annual Meeting
Benzinga · Oct 6, 2026
Amylyx Pharma To Present Phase 3 Topline Data Highlighting Avexitide’s Efficacy And Safety At ObesityWeek 2026 Annual Meeting
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced it will present two presentations at the upcoming ObesityWeek® 2026 Annual Meeting, taking place November 14-17,
Benzinga · Oct 5, 2026
Amylyx Pharma Q2 2026 Earnings Call Transcript
Amylyx Pharma (NASDAQ:AMLX) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to our
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
